Sarcoid and CVID can look alike as both get Granulomatous lessons. Dr Anna Postolova at #RWCS2020 @RWCSmtg https://t.co/TREQwYYrgc

A high percentage of complement deficiencies will develop lupus. Dr Anna Postolova at #RWCS2020 @RWCSmtg https://t.co/IItg1Ezd3F

Common immunodeficies. Dr Anna Postolova at #RWCS2020 @RWCSmtg https://t.co/rpjrmcl8t6

Was are placebo responses so high in RA MTX-IR who receive MTX in RCTs. ?adherence ?placebo effect ?keen study personnel. Filgo vs Ada - both effective and not stat different but high placebo too added to MTX. #RWCS2020 @RWCSmtg @RheumNow https://t.co/hHPR9yO0gb

Fewer VTE and HZ in filgotinib trials. More studies needed for proof of efficacy. Drs. Fleischmann and Genovese. #RWCS2020 @RheumNow @RWCSmtg https://t.co/O50yPwTxmm

Here’s what I think is missing in RA for JAKi trials. Mono therapy post MTX-IR vs TNFi. Comparisons head2head with other biological and post JAKi RCT of another JAKi. @RWCSmtg @RheumNow #RWCS2020 #JAK

Fenebrutinib, a BTK inhibitor, is better that placebo, but not ADA when given in a phase 2 trial. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/lOtFoB80s3

Do we need another IL6 inhibitor for rheumatic diseases. Tocilizumab is off patent in USA and Europe. We have Sarilumab but Sirukumab did not go forward in RA. Another kid on block - Olokizumab IL6 receptor blocker with +RA RCT #RWCS2020 @RWCSmtg @RheumNow https://t.co/OwhnRjwPrt

Sky kinases are terminally sick. DNR for RA trials. Another one bites the dust. @RWCSmtg @RheumNow #RWCS2020 https://t.co/GbnEfkOR7p

Learning from rheum colleagues ⁦@RWCSmtg⁩ upadacitinib rate of vte similar to adalimumab and mtx. Suggests it’s the disease rather than the drug. https://t.co/KG8CionFbN

“Autoimmunity can be the initial presentation of immunodeficiency.” Dr. A. Postolova #RWCS2020 @RheumNow @RWCSmtg

25% of PID pts will develop an autoimmune disease. Here are Dr. Postolova’s 10 warning signs. Left for children and right for adults. #RWCS2020 @RheumNow @RWCSmtg https://t.co/mxQ2urQQ9G

Primary immunodeficiency warning signs in adults; 25% of OID will develop an autoimmune disease. Dr Anna Postolova at #RWCS2020 @RWCSmtg https://t.co/c84Sybg95W

Fenebrutinib, a BTK inhibitor, is better that placebo, but not ADA when given in a phase 2 trial. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/lOtFoB80s3

A favorable safety profile for Filgotinib, maybe less zoster and VTE. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/yNn8tl3R8c